Deep Phenotyping of Cutaneous Lupus Erythematosus

NCT ID: NCT06411106

Last Updated: 2024-05-13

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-06-30
• Study Completion Date: 2025-09-30

Brief Summary

Cutaneous lupus erythematosus (CLE) is an autoimmune disease of which the pathogenesis and pathophysiology are not fully understood. Given the complex and heterogeneous character of the disease, identification, and development of specific biomarkers for diagnosis, disease subtyping, disease severity, and treatment response in CLE is challenging. Therefore, the main objective of the current study is to further characterize CLE by using a deep phenotyping approach. Moreover, the role of TLR7 activation in the pathophysiology of the various clinical subtypes of CLE will be specifically studied. With this approach the investigators aim to characterize objectively measured disease characteristics and detect novel biomarkers for CLE(-subtypes).

Detailed Description

Cutaneous lupus erythematosus (CLE) is a rare but burdensome autoimmune disease that includes various subtypes including acute cutaneous LE (ACLE), subacute cutaneous LE (SCLE), intermittent cutaneous LE (ICLE) i.e., lupus tumidus (LET) and chronic cutaneous LE (CCLE). These subtypes differ in lesion morphology and histopathology, however disease stratification is often a challenge.

Knowledge on mechanisms involved in the pathogenesis and pathophysiology of CLE is growing, however much remains unknown. The current concept regarding the onset of the disease comprises a genetic background predisposing to CLE triggered by factors such as UV light, what leads to cellular stress and eventually to the release of DNA components in keratinocytes (Fetter et al., 2022). Activation of both Toll-like receptor (TLR)-dependent and TLR-independent inflammatory signalling cascades leads to increased expression of several cytokines, in particular type I interferon (IFN). Type I interferon mediates increased expression of proinflammatory chemokines via the JAK-STAT pathway, leading to recruitment of immune cells, release of cytokines and a chronic reactivation of innate immune pathways.

Findings on the pathogenesis of the disease have led to the development of several targeted therapies that are currently being investigated in clinical trials. However, blockage of one important pathway might not suffice for decreasing disease activity given the limited efficacy of selective IFN antibodies in clinical trials (Kalunian et al., 2016), (Khamashta et al., 2016) (Werth et al., 2017).

Only few biomarkers for CLE have been validated and widely incorporated into clinical practice (Zhu et al., 2021). Type I interferon-inducible proteins can be potentially used to assess disease severity of SCLE and CDLE (Braunstein et al., 2013). Furthermore, low complement in CLE patients may be related to poor prognosis and increased risk of developing systemic disease (Vera et al., 2010) (Vera et al., 2010).

Therefore, the objectives of the current study are to evaluate disease-related characteristics in CLE patients and to evaluate the variability between patients using a deep phenotyping approach, and to investigate the immune response of CLE patients following an ex vivo and in vivo imiquimod skin challenge. The study consists of an observational (part A) and interventional (part B) part in CLE patients and healthy volunteers.- With this approach the investigators aim to characterize objectively measured disease characteristics and detect novel biomarkers for CLE(-subtypes).

This study is part of the Next Generation Immuno Dermatology consortium SKINERGY trials.

Conditions

Cutaneous Lupus Erythematosus

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Arm

CDLE patients and healthy volunteers In part B of this study, 5 mg imiquimod (100 mg Aldara®) per skin area (in total two skin areas) will be applied for two consecutive days under occlusion.

Group Type: EXPERIMENTAL

IMIQUIMOD cream 50mg/g

Intervention Type: DRUG

5 mg imiquimod (100mg Aldara®) per treatment site with a 12mm Finn chamber

Interventions

IMIQUIMOD cream 50mg/g

5 mg imiquimod (100mg Aldara®) per treatment site with a 12mm Finn chamber

Intervention Type: DRUG

Other Intervention Names

Aldara

Eligibility Criteria

Inclusion Criteria

1. Signed informed consent prior to any study-mandated procedure.

2. Male or female subjects, 18 to 65 years of age at the time of signing informed consent; in general, stable good health as per judgement of the investigator based upon the results of a medical history, physical examination, vital signs, ECG, and laboratory assessments performed at screening. Repeated laboratory testing may be performed at the discretion of the clinical investigator.

3. Body mass index (BMI) > 18.0 and < 32.0 kg/m2

4. Fitzpatrick skin type I-III (Caucasian).

5. Subjects and their partners of childbearing potential must use effective contraception for the duration of the study.

6. No clinically significant skin disease as judged by the investigator.

7. No history of hypertrophic scarring or keloid.

8. Subject is willing to refrain from application of any topical product (e.g., ointments, cream or washing lotions) on the target lesion(s)skin 24 hours prior to every study visit day.

9. Subject has the ability to communicate well with the investigator in the Dutch language and is willing to comply with the study requirements.

1. Signed informed consent prior to any study-mandated procedure.

2. Male or female CLE patients, 18 to 65 years of age at the time of signing informed consent; in general, stable good health as per judgement of the investigator based upon the results of a medical history, physical examination, vital signs, ECG, and laboratory assessments performed at screening. Repeated laboratory testing may be performed at the discretion of the clinical investigators.

3. Body mass index (BMI) > 18.0 and < 35.0 kg/m2.

4. Only applicable for CDLE patients who will also participate in part B: Fitzpatrick skin type I-III (Caucasian).

5. Subjects and their partners of childbearing potential must use effective contraception for the duration of the study.

6. Patient has the ability to communicate well with the investigator in the Dutch language and is willing to comply with the study requirements.

7. Subject is willing to refrain from application of any topical product (e.g., ointments, cream or washing lotions) on the target lesion(s) 24 hours prior to every study visit day.

8. Participants must have a diagnosis of SCLE, CDLE or LET that fulfils the following:

• Confirmed CLE diagnosis by clinicopathological correlation.
• At least one CLE skin lesion of at least 3x3 cm suitable as assessed by the investigator for measurements performed in the study.
• Location of the lesion(s) selected for biopsy outside the face (possible are e.g., neck, chest, back, limbs, scalp, ear etc.).
• Receiving one of the following systemic treatments for CLE (stable for a minimum of 8 weeks):

• None
• Hydroxychloroquine
• An overall CLE Disease Area and Severity Index Activity (CLASI-A) Score ≥3 without counting any diffuse alopecia or oral ulcers

Exclusion Criteria

1. (History of) immunological abnormality (e.g., immune suppression) that may interfere with study objectives, in the opinion of the investigator.

2. Have any current and/or recurrent clinically significant skin condition, including tattoos.

3. Antibiotic use, operation, or clinically significant intervention by surgeon/dentist within one month before Day 1.

4. Positive hepatitis B surface antigen (HbsAg), hepatitis C antibody (HCV ab), or human immunodeficiency virus antibody (HIV ab) at screening.

5. Participation in an investigational drug study within 3 months prior to screening or more than 4 times a year.

6. Loss or donation of blood over 500mL within three months prior to screening.

7. Subject is willing to refrain from the use of any medication within 28 days prior to Day 1, if the investigator judges it may interfere with the study objectives.

8. History of alcohol abuse or consumption exceeding 5 standard drinks per day on average within 3 months of screening.

9. Positive urine test for drugs or history of abuse at screening. Urine drug test may be repeated at the discretion of the investigator.

10. Pregnant, a positive pregnancy test, intending to become pregnant during the study conduct, or breastfeeding.

11. (A history of) any clinically significant medical condition, factor or abnormality that might interfere with study conduct or interpretation, as judged by the investigator.

12. Previous use of Aldara (imiquimod cream) 3 months prior to the Day 1 visit in part B.

13. Any active or chronic and/or uncontrolled condition that, in the opinion of the investigator, may influence study conduct or interpretation

1. Presence of a relevant skin infection or disease in the target areas other than the observational disease (CLE), inclusively, but not limited to atopic dermatitis, psoriasis vulgaris and dermatomycosis.

2. Having received treatments for CLE or any other disease within the following intervals prior to Day 1:

1. <2 weeks for topical treatment, e.g., corticosteroids at target area(s)

2. <6 weeks for systemic therapy with immunosuppressive agents (other than hydroxychloroquine stable use for a minimum of 8 weeks)

3. <12 weeks for biologics

4. <8 weeks procedure or surgery in or close to the target areas

5. <3 months for chemotherapeutical treatment

3. Presence of severe lupus-associated renal disease.

4. Presence of antiphospholipid syndrome.

5. Active or unstable lupus-associated neuropsychiatric disease.

6. Severe organ SLE manifestation(s) (e.g., active myocarditis) or unstable disease as judged by the investigator.

7. Diagnosis of systemic lupus erythematosus (SLE) according to the EULAR-ACR criteria (2019) or substantial indication for systemic involvement (part B only).

8. Low complement (C3 and/or C4) levels at screening (< ULN) (part B only).

9. Positive ANA and anti-dsDNA and/or anti-SM at screening (part B only).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Centre for Human Drug Research, Netherlands

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

R. Rissmann, RPh, PhD

Role: PRINCIPAL_INVESTIGATOR

Centre for Human Drug Research

Locations

Centre for Human Drug Research

Leiden, South Holland, Netherlands

Site Status: RECRUITING

Countries

Netherlands

Central Contacts

R. Rissmann, RPh, PhD

Role: CONTACT

clintrials@chdr.nl

+31715246400

D. T. de Bruin, MD

Role: CONTACT

clintrials@chdr.nl

+31715246400

Facility Contacts

R. Rissmann, RPh, PhD

Role: primary

clintrials@chdr.nl

+31715246400

D. T. de Bruin, MD

Role: backup

clintrials@chdr.nl

+31715246400

Other Identifiers

NL84645.056.23

Identifier Type: OTHER

Identifier Source: secondary_id

CHDR2307

Identifier Type: -

Identifier Source: org_study_id